CHRONOS-4 Phase 3 trial

November 6, 2017

Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017

News

Bayer will present long-term safety and efficacy data from the CHRONOS-1 trial of Aliqopa (copanlisib) in patients with indolent lymphomas at the American Society of Hematology (ASH) 2017 Annual Meeting ... Read more

September 18, 2017

Bayer Presents Copanlisib Combination Trials at Scientific Meeting

News

Two Phase 3 trials will assess the potential of Bayer’s copanlisib in combination with other treatment in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma, based on positive data from a ... Read more

September 15, 2017September 15, 2017

FDA Approves Bayer’s Aliqopa for Relapsed Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Bayer’s Aliqopa (copanlisib) for patients with follicular lymphoma who have relapsed after at least two earlier therapies. The agency granted Aliqopa an accelerated ... Read more